BillionToOne 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- BillionToOne reported Q3 2026 revenue of $123.0 million, up 47% year over year and 12% quarter over quarter, on test volume growth of 25% and ASP growth of 18%.
- Prenatal revenue increased 42% year over year to $105.9 million, while oncology revenue increased 96% to $17.1 million.
- Gross margin was 70.9%, compared with 69.9% in Q3 2025; prenatal gross margin was 75% and oncology gross margin was 45%.
- Operating income was $11.0 million, a 9% operating margin, and adjusted EBITDA margin was 18%; this was the company’s 5th consecutive quarter of positive GAAP operating income.
- Net income available to common shareholders was $17.4 million, or $0.32 per diluted share, compared with $1.5 million, or $0.10 per diluted share, in Q3 2025.
- Free cash flow was $8.6 million, and BillionToOne ended the quarter with $562 million in cash and equivalents.
- TrueUp revenue was $7.6 million in Q3 2026, compared with $2.8 million in Q2 2026 and $3.7 million in Q3 2025; excluding TrueUp revenue, total revenue grew 8% sequentially.
- Overall COGS per test was $169, compared with $161 in the prior quarter, reflecting a mix shift toward oncology and transient costs from recent product launches.
- Management reported a prospective Unity Fetal Risk Screen study with 94.4% sensitivity and 99.5% specificity across 2,212 pregnancies, with outcomes obtained for more than 98% of pregnancies studied.
- A published NorthStar Response head-to-head study reported that the tests agreed on the direction of ctDNA change in 94% of sequential pairs, with NorthStar Response delivering on par to superior results versus a tumor-informed assay.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
I would now like to hand the conference over to your speaker today, Gabby Gable with Investor Relations.
Good afternoon, everyone. Thank you for participating in today's conference call. Joining me on the call from BillionToOne, we have Ozan Atay, Co-Founder and Chief Executive Officer, and Ross Taylor, Chief Financial Officer. Earlier today, BillionToOne released financial results for the third quarter ended September 30, 2026. A copy of the press release is available on the company's website. Before we begin, I want to remind you that during this call, we may make forward-looking statements within the meaning of federal securities laws. Such statements about future events may include statements about our financial outlook and performance, market size, our products and services, reimbursement coverage, future clinical performance, and other similar statements. We caution you that such statements reflect our current best judgment, and actual results may differ materially from those expressed or implied in any forward-looking statements.
Risk factors that may cause our results to differ are discussed in our filings with the SEC, including our previously filed annual report on Form 10-K, our quarterly report on Form 10-Q to be filed following this call, and the current report on Form 8-K filed today. Any forward-looking statement made during this call is made as of today, November 4, 2026. If this call is replayed or reviewed after today, the information made during this call may not contain current or accurate information. BillionToOne disclaims any obligation to publicly update any forward-looking statements, whether because of new information, future events, or otherwise, except as required by law. With that, I will turn the call over to Ozan.
Good afternoon, everyone, and welcome to our third quarter 2026 earnings call. Before I begin, I want to recognize the people who make our work possible. To the patients and providers who rely on us during the most important moments of their care, thank you for your confidence in us. To our employees, your commitment is what allows us to deliver superior tests that lead to better care and remove the fear of the unknown for our patients. Before turning to our quarterly results, I would like to remind you of our four pillars that guide our strategy and set BillionToOne apart from other molecular diagnostics companies. The foundation is our first pillar. Our patented QCT, or Quantitative Counting Template technology, has allowed us to create category-defining products in prenatal and in oncology. Those products drive our second pillar, scalable rapid growth.
We have grown rapidly to $492 million annualized revenue run rate in just six years. We also believe we have only scratched the surface, with a $100 billion of annual cell-free DNA testing opportunity in prenatal and oncology in the U.S. alone. Our third pillar is a superior gross margin profile, which together with relentless discipline on both ASPs and COGS, keeps our gross margin above 70% today, and we believe with more room left to expand in the long term. Our fourth pillar is GAAP profitability. The margin profile, paired with our fiscally disciplined culture and AI-enabled operations, has made us GAAP profitable and cash flow positive, with roughly one-tenth of the accumulated deficit of our public peers. Our long-term goal has not changed. We are building a generational company that transforms the standard of care in molecular diagnostics for millions of patients.
In the third quarter, we executed on every one of our four pillars. It was another strong quarter. We delivered record revenue and a combination of rapid growth and GAAP profitability that remains exceptionally rare in molecular diagnostics, as well as the type of product and clinical study developments that can position us for exceptional growth and performance in the years to come. Briefly, pillar by pillar. In our first pillar, we published two important studies. First, in the leading journal for OB-GYNs, the Green Journal, we published the first and only peer-reviewed prospective study in single-gene NIPT. In oncology, in The Journal of Liquid Biopsy, we published what we believe is the first head-to-head study of a tissue-free test, Northstar Response, against a tumor-informed assay for response monitoring with on-par to superior results.
We are launching Northstar Clear, our tissue-free MRD test, on December 15th, which I will come back to shortly. On rapid growth, prenatal revenue was up 42%, and oncology revenue was up 96%, resulting in total Q3 revenue growth of 47% year-over-year. Our gross margins remained very consistent in the quarter at 71%, even with COGS per test rising 10% to $169 due to faster oncology growth. Lastly, we generated GAAP operating income of $11 million, a 9% GAAP operating margin, and a remarkable 18% adjusted EBITDA margin. It was our fifth consecutive quarter of positive GAAP operating income. We were also cash flow positive and finished the quarter with $562 million in cash. Now, let me walk through each pillar in more detail. Beginning with our first pillar, our SMNGS platform and products.
Clinical evidence is what turns a powerful platform into a standard of care, and this quarter, we meaningfully expanded that evidence across prenatal and oncology while preparing our next major product launch. Starting with prenatal. On August 18th, we published the first and largest prospective study of a single gene non-invasive prenatal test in its intended use population, validating it as a first-line screen. The study appeared in the leading journal for OB-GYNs, the Green Journal, and was conducted in collaboration with nine U.S. institutions. This is exactly the kind of high-quality evidence that changes clinical practice. We obtained outcomes for more than 98% of the 2,212 pregnancies studied. Unity Fetal Risk Screen demonstrated 94.4% sensitivity and 99.5% specificity, with consistent performance across a racially and ethnically diverse U.S. population. To put this in perspective, with traditional screening, the highest fetal risk a family can receive is one in four.
Unity provides a personalized fetal risk as high as nine in 10 and as low as one in 10,000. Unlike others' studies where most affected fetuses come from previously identified high-risk couples, this prospective multi-site study was conducted in the intended use general population with near-complete outcome collection. Therefore, it constitutes the highest form of evidence in showing that the assay works in identifying affected fetuses with high sensitivity and specificity. We believe this publication reinforces Unity as the leading cell-free DNA screen for recessive single gene conditions. In oncology, on October 7th, in The Journal of Liquid Biopsy, we published what we believe is the first head-to-head comparison with the most widely used tumor-informed assay in patients on active treatment for advanced cancer. This was a pan-cancer real-world comparison, with the data coming from providers who use both assays in their clinical practice.
The results show that Northstar Response delivers on par to superior results versus the tumor-informed assay, which, to our knowledge, makes this the first time a tissue-free test has ever demonstrated superior head-to-head performance against a tumor-informed assay. The two tests agreed on the direction of ctDNA change in 94% of sequential pairs. However, in all divergent cases, the patient's clinical records supported Northstar Response's findings, whereas the tumor-informed assay's results were either false positives or false negatives relative to the patient's clinical response or progression. Tumors evolve over time, and this study shows that relying on a test that depended on years-old tissue can sometimes lead to inaccurate results. This study also shows that physicians do not need to trade away performance to receive the turnaround time and other logistical benefits of a tissue-free test.
The study is a powerful demonstration of the precision that our QCT technology delivers, and it further strengthens the evidence base for Northstar Response. We expect this data to accelerate adoption of Response and further ensure that the Medicare coverage for Response is a matter of when rather than if. We are excited to announce that Northstar Clear, our tissue-free MRD test, will be commercially launching on December 15th. Clear is a pan-cancer test and only requires a blood draw, so it is available for all solid tumors from day one, with no need to wait for a tissue sample or build a patient-specific assay. What we set out to deliver with Clear is tissue-free MRD with tumor-informed performance. MRD represents an estimated $30 billion annual market, and we believe we have developed the most sensitive tissue-free MRD test. We will launch with head-to-head data against the tumor-informed comparator.
While this head-to-head data will initially be in colorectal cancer, the assay will be available for all solid tumors. We will continue further evidence generation across all solid tumors through 2027 and beyond. Clear is also an important step in expanding our platform. Together with Select and Response, Clear means the Northstar portfolio will now span early and late-stage care, all built on the same QCT technology. The work behind Clear also lays the groundwork for our longer-term opportunity in early detection. Fundamentally, a tissue-free MRD and early detection are very similar technical problems, with both requiring the detection of very low levels of tumor DNA without the benefit of tissue access. As such, our MRD launch significantly de-risks our long-term plans for a highly sensitive early detection test. Next, our second pillar, scalable rapid growth.
In the third quarter, total test volume grew 25% year-over-year to approximately 206,000 tests, up more than 10,000 tests sequentially, and with sequential growth in both prenatal and oncology. There were three overall drivers to strong test volume: strong execution by our teams, a larger field sales force, and continued positive reception of the product enhancements we have introduced across both prenatal and oncology. In prenatal specifically, we are continuing our focus on pushing into larger health systems, which remains a large opportunity. This is supported by our newly launched 130-gene Unity Fetal Risk Screen, category-defining Unity Confirm test, and Epic Aura integration. In oncology, volume growth was exceptional again, driven by our expanding sales team and continued adoption of our PGx, CH, and tissue of origin enhancements. Both prenatal and oncology were significant drivers of growth in the third quarter.
Prenatal revenue was $106 million, up 42% year-over-year, representing an annualized run rate of $424 million. Oncology revenue nearly doubled, growing 96% year-over-year to $17 million, representing an annualized run rate of approximately $68 million. Our total revenue performance in the third quarter reflects our ability to execute remarkable growth over the past six years. We have built a $492 million of annualized revenue run rate business from essentially zero in approximately six years. Together, prenatal and oncology drove a record total revenue of $123 million in the third quarter, up 47% year-over-year and 12% quarter-over-quarter. This growth was driven by 25% growth in test volume and 18% growth in ASP. Now to the third pillar, our superior gross margin profile. Turning to our ASPs in the quarter, overall ASP increased 7% sequentially and 18% year-over-year to $589 per test.
Both prenatal and oncology ASPs increased quarter-over-quarter. Excluding true-up revenue, overall ASP was $552, up 3% sequentially and 15% year-over-year. This increase was driven by more payer contracts, higher reimbursement for RhD NIPT through its PLA code, and a growing proportion of oncology, which has a higher overall ASP than prenatal. Growing ASP is only half of the equation, with continuous improvement on COGS per test remaining core to how we operate. Overall COGS per test was $169 in the third quarter, compared to $161 last quarter, reflecting the continued mix shift toward oncology, along with some transient costs from recent product launches. In oncology, COGS per test continues to improve, and importantly, Northstar Response is already at approximately gross margin breakeven. Because oncology is growing faster than prenatal, we continue to anticipate a gradual increase on overall COGS per test over time.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
